At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
LY2216684 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Lorazepam in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY2216684, Placebo, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684. Information about any side effects that may occur will also be collected.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedJan 2011
Primary CompletionFeb 2011
TodayJul 2026
First PostedJan 12, 2011
Enrollment StartDec 1, 2010
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.5 years ago
Interventions
LY2216684drug
Administered orally
Placebodrug
Administered orally
Lorazepamdrug
Administered orally